Page Title
Clinical Trial Finder
Ask About Participating in This Study
Genetic TherapyEnrolling
Study to evaluate SP-101 in adults with cystic fibrosis who are ineligible for or cannot tolerate CFTR modulator therapy., protocol number Spirovant CFAAV-001 USThe following information will be used to determine eligibility for this study. Fill out the form and click “Preview Message.” This will draft an email you can send directly to the Research Coordinator. Please note, this does not guarantee entry into this particular study.
* indicates required field
Personal Information
Add more details about who you are and how you would like to be contacted (e.g. phone, text, email).
(this will open in your email program)
Genetic TherapyEnrolling
Study to evaluate SP-101 in adults with cystic fibrosis who are ineligible for or cannot tolerate CFTR modulator therapy., protocol number Spirovant CFAAV-001 US
This study will evaluate the safety and tolerability of SP-101, an inhaled gene therapy, in adults with cystic fibrosis ages 18 to 65 who are ineligible for or cannot tolerate CFTR modulator therapy.
-
Age:
18 Years to 65 Years
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
50 to 100%
-
Number of Visits:
11
-
Length of Participation:
1 years
Related Topics

CONTACT THE CLINICAL TRIAL NAVIGATOR
Get personalized assistance and answers to your clinical trial questions.
Learn MoreSign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Check the Drug Development Pipeline
We’re attacking CF from every angle. Learn about the status of CF drugs in development.
Learn More